BIO 300 Oral Suspension in Discharged COVID-19 Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Randomized, double-blinded, placebo-controlled, two-arm study to evaluate the effectiveness
and safety of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary
function in 2019 Coronavirus Disease (COVID-19) patients recently discharged from the
hospital. Patients will be randomized 1:1 to receive BIO 300 or placebo. All patients will
receive current background standard of care based on local clinical site practice.
Phase:
Phase 2
Details
Lead Sponsor:
Humanetics Corporation
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) NYU Langone Health